Greenwich LifeSciences, Inc. (GLSI)
Largest Insider Buys in Sector
GLSI Stock Price History Chart
GLSI Stock Performance
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 …
Insider Activity of Greenwich LifeSciences, Inc.
Over the last 12 months, insiders at Greenwich LifeSciences, Inc. have bought $3.53M and sold $0 worth of Greenwich LifeSciences, Inc. stock.
On average, over the past 5 years, insiders at Greenwich LifeSciences, Inc. have bought $1.41M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Patel Snehal (CEO and CFO) — $3.48M. Thompson Jaye (VP Clinical Reg Affairs) — $55,140.
The last purchase of 1,000 shares for transaction amount of $12,910 was made by Thompson Jaye (VP Clinical Reg Affairs) on 2024‑11‑21.
List of Insider Buy and Sell Transactions, Greenwich LifeSciences, Inc.
| 2024-11-21 | VP Clinical Reg Affairs | 1,000 0.0077% | $12.91 | $12,910 | +4.16% | |||
| 2024-09-26 | CEO and CFO | 1,500 0.0114% | $14.63 | $21,945 | 0.00% | |||
| 2024-08-12 | VP Clinical Reg Affairs | 800 0.0065% | $13.85 | $11,080 | +3.55% | |||
| 2024-08-06 | CEO and CFO | 2,000 0.0151% | $13.81 | $27,620 | -2.43% | |||
| 2024-08-05 | CEO and CFO | 5,500 0.0424% | $13.18 | $72,490 | +4.45% | |||
| 2024-08-02 | VP Clinical Reg Affairs | 1,000 0.0082% | $15.15 | $15,150 | -3.66% | |||
| 2024-07-23 | CEO and CFO | 1,500 0.0115% | $15.89 | $23,835 | -2.14% | |||
| 2024-07-18 | VP Clinical Reg Affairs | 1,000 0.008% | $16.00 | $16,000 | -10.24% | |||
| 2024-06-13 | CEO and CFO | 174,825 1.3679% | $14.30 | $2.5M | -5.22% | |||
| 2024-04-01 | CEO and CFO | 3,000 0.0234% | $19.08 | $57,240 | -26.47% | |||
| 2024-03-22 | CEO and CFO | 2,500 0.0198% | $19.98 | $49,950 | -28.59% | |||
| 2024-03-20 | CEO and CFO | 1,500 0.0112% | $17.68 | $26,520 | -23.50% | |||
| 2024-03-05 | CEO and CFO | 30,500 0.2372% | $12.49 | $380,945 | +11.81% | |||
| 2024-03-04 | CEO and CFO | 4,100 0.0318% | $13.03 | $53,423 | +9.18% | |||
| 2024-02-16 | CEO and CFO | 10,800 0.0835% | $11.16 | $120,528 | +24.91% | |||
| 2024-02-15 | CEO and CFO | 12,700 0.1073% | $11.07 | $140,589 | +20.95% | |||
| 2023-11-10 | CEO and CFO | 5,000 0.0391% | $10.17 | $50,838 | +34.86% | |||
| 2023-11-03 | CEO and CFO | 3,500 0.0274% | $9.11 | $31,885 | +49.39% | |||
| 2023-10-27 | VP Clinical Reg Affairs | 500 0.0039% | $8.57 | $4,285 | +57.63% | |||
| 2023-10-26 | CEO and CFO | 2,500 0.0188% | $7.97 | $19,925 | +62.39% |
Insider Historical Profitability
| Patel Snehal | CEO and CFO | 5536102 42.1166% | $12.21 | 60 | 0 | +26.3% |
| Thompson Jaye | VP Clinical Reg Affairs | 264148 2.0095% | $12.21 | 21 | 0 | <0.0001% |
| McWilliams David | director | 620301 4.719% | $12.21 | 3 | 0 | +414.35% |
| Hallock Kenneth | director | 397304 3.0225% | $12.21 | 4 | 0 | +468.96% |
| Rothe Eric | director | 313226 2.3829% | $12.21 | 1 | 0 | +604.51% |
Institutional Investor Ownership
| The Vanguard Group | $4.45M | 1.73 | 223,102 | +0.64% | +$28,314.80 | <0.0001 | |
| Millennium Management LLC | $1.27M | 0.5 | 63,811 | +454.35% | +$1.04M | <0.01 | |
| Geode Capital Management | $1.16M | 0.45 | 58,244 | +24.41% | +$227,928.40 | <0.0001 | |
| BlackRock | $1.13M | 0.44 | 56,459 | -1.21% | -$13,738.67 | <0.0001 | |
| Goldman Sachs | $827,610.00 | 0.32 | 41,505 | New | +$827,610.00 | <0.0001 |